

Association of Lecithin Cholesterol Acyltransferase rs5923 Polymorphism in Iranian Individuals with Extremely Low High-Density Lipoprotein Cholesterol: Tehran Lipid and Glucose Study

Mohsen Naseri¹, Mehdi Hedayati², Maryam Sadat Daneshpour²,
Fatemeh Bandarian³, Fereidoun Azizi^{*2}

¹Genomic Research Center, Birjand university of Medical Sciences, Birjand, Iran; ²Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ³Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Received 29 December 2014; revised 5 April 2015; accepted 19 April 2015

ABSTRACT

Background: The serum concentration of high-density lipoprotein cholesterol (HDL-C) is one of the important heritable risk factors for cardiovascular disease and is a target for therapeutic intervention. In this study, we aimed to evaluate the effects of lecithin cholesterol acyltransferase (*LCAT*) gene polymorphism rs5923 on *LCAT* enzyme activity and serum HDL-C concentration. **Methods:** The study population was selected from consecutive individuals with HDL-C \leq 5th percentile (n = 73) and extremely high HDL-C \geq 95th percentile (n = 57) who had participated in the Tehran Lipid and Glucose Study. The rs5923 polymorphism was genotyped using direct sequencing. *LCAT* activity was measured by fluorometric assay kit, and lipid concentrations were measured using the enzymatic colorimetric method. **Results:** The genotype frequencies were significantly different between the high HDL-C group (CC 94.7%, CT 5.3%) and the low HDL-C group (CC 83.6%, CT 16.4%) ($P = 0.048$). The T-allele frequencies in subjects with low and high HDL-C were 0.082 and 0.026, respectively ($P = 0.16$). The association of the single-nucleotide polymorphism rs5923 with low HDL-C was not statistically significant after adjustment for age, sex, and BMI (odds ratio = 2.65, 95% confidence interval = 0.32-21.5, $P = 0.36$, regression logistic analysis). Also, the effects of *LCAT* enzyme activity did not depend on the HDL-C level ($P = 0.24$). **Conclusion:** rs5923 polymorphism is not associated with low HDL-C levels in Iranian population. *Iran. Biomed. J.* 19 (3): 172-176, 2015

Keywords: Polymorphism, Single nucleotide, Lipoproteins

INTRODUCTION

The serum concentration of high-density lipoprotein cholesterol (HDL-C) is one of the important heritable risk factors for cardiovascular disease (CVD), and it is a target for therapeutic intervention [1]. Although high plasma levels of HDL-C are protective against CVD, a low plasma level of HDL-C (<40 mg/dl) is a strong and an independent risk factor for development of premature atherosclerosis leading to CVD [1, 2]. In individuals participated in the Tehran Lipid and Glucose Study (TLGS), the prevalence of cardiovascular risk factors, particularly low HDL-C levels was high (32%) among the urban population of Tehran [3].

There is overwhelming evidence that in addition to environmental factors such as decreased exercise,

alcohol consumption, cigarette smoking, diabetes, dietary saturated fat, and obesity, the genetic background also plays an important role in serum HDL-C levels [4]. The heritability of HDL has been estimated to be in a range of 40-60%. Moreover, in recent decades, various studies have been conducted to investigate gene regulation [5].

Molecular defects in gene apolipoprotein A-I, adenosine triphosphate binding cassette transporter A1, and lecithin cholesterol acyltransferase (*LCAT*) may lead to rare genetic forms of HDL deficiency [6]. *LCAT*, first described in 1962 [7], is a soluble enzyme that plays a central role in the formation and maturation of HDL. It is a catalyst for transferring acyl groups from C2 position of lecithin to the 3-hydroxy group of cholesterol that produces most cholesterol ester in the plasma [8]. This enzyme converts

*Corresponding Author; Tel: (+98-21) 2243 2470; Fax: (+98-21) 2402 463; E-mail: azizi@endocrine.ac.ir

cholesterol and lecithins to cholesteryl esters and lysophosphatidylcholines on the HDL surface [9]. The human *LCAT* gene, localized at 16q22, spans 4.2 kb and contains six exons, including ~1.5-kb coding sequence that encodes a 416-amino-acid protein. *LCAT* is synthesized by the liver and circulates in blood plasma as a HDL composite. In the reverse cholesterol transport system, HDL particles receive the cholesterol of peripheral cells and carry them to the liver [9]. *LCAT* has also a significant role in the conversion of pre β HDL into mature spherical α -HDL and metabolism of intravascular HDL [10].

The single-case investigations or studies of small families have led to the identification of most mutations in *LCAT* gene [8-10]. Two syndromes of *LCAT* deficiency are fish-eye disease (OMIM no. 136120) showing partial enzymatic defect and familial *LCAT* deficiency (OMIM no. 245900) in which enzyme activity is completely absent. Low plasma levels of HDL-C, apolipoprotein A-I and A-II levels as well as hypoalphalipoproteinemia and cholesterol esterification impairment are observed in individuals with fish-eye disease and familial *LCAT* deficiency [10]. So far, more than 80 causative mutations in *LCAT* have been described in the Human Gene Mutation Database [11].

Furthermore, in recent years, 16 loci associated with HDL-C ($P < 5 \times 10^{-8}$) levels have been identified in the meta-analysis of a genome-wide study on over 100,000 individuals [12], showing that the strongest indicator of isolated variation in HDL-C levels is a single nucleotide polymorphism (SNP) in the *LCAT* gene [13]. More than 160 SNPs have been currently found in *LCAT* and submitted to the Single Nucleotide Polymorphism Database [14]. rs5923 is one of these SNP initially reported as 4886C>T(L369L) mutation in the human *LCAT* gene in 2000 [15]. In 2011, Agirbasli and co-workers [16] reported that this mutation is the most frequent *LCAT* gene variant in the Turkish population, and T-allele frequency was predominant in individuals with low HDL-C. In the present investigation, we aimed to evaluate the effects of *LCAT* gene polymorphism rs5923 on *LCAT* enzyme activity and HDL-C level in an Iranian population.

MATERIALS AND METHODS

This cross-sectional study was conducted on participants enrolled in the TLGS, which is a prospective population-based, longitudinal cohort study with more than 15,000 participants and designed for the assessment of cardiovascular risk factors and diseases in the urban residents of Tehran [17].

Individuals aged 15-70 years with HDL-C levels of < the 5th percentile for age and sex ($n = 73$) and those

with >95th percentile ($n = 57$) for age and sex were selected from the TLGS population. Individuals who had the same trait in 4 TLGS phases persistently and had at least a family member with the same trait were included in the study. Also, obese individuals ($\text{BMI} \geq 30 \text{ kg/m}^2$) and those receiving drugs affecting HDL-C levels were excluded from the study.

An informed consent was obtained from the participants and ethics approval was given by the Ethics Committee of the Research Institute for Endocrine Sciences at Shahid Beheshti University of Medical Sciences, Tehran, Iran. A standardized questionnaire was used to gather data on medication usage, demographics, sex, age, lipid disorders, and hypertension treatment. Details of the collection, preparation, and lipid determination methods together with details on quality control have been described previously [18].

The activity of plasma *LCAT* was measured quantitatively via a fluorometric assay kit (Calbiochem, Germany). Briefly, fluorescence was emitted from the fluorescent substrate at 470 nm. Human plasma samples and substrates were incubated at 37°C for 18 hours. Upon hydrolyzation of the substrate, a monomer was discharged by *LCAT* producing 390-nm fluorescence. Change in the intensity of 470/390 emission was used to assess *LCAT* activity.

For assessment of the *LCAT* polymorphism, Buffy coats separated from the non-coagulated whole blood samples were stored at -70°C before processing. The genomic DNA was extracted using salting out method [17]. The sequences of human *LCAT* coding region were obtained from the genome browser UCSC (<http://genome.ucsc.edu>) [19]. Primers were designed to amplify coding sequence and exon-intron boundaries of the *LCAT* (NM_000229.1) using web-based Primer3 software (version 0.4.0) and NCBI primer-blast programs [20].

Hybridization was carried out in a DNA thermal cycler (Corbett, Australia). The genomic region flanking the rs5923 (accession no. NT_010498.15 :g.21588152G>A) polymorphism in exon 6 of *LCAT* was amplified with forward (5'-TGAGCCTACACTC AGCAGGTTGTG -3') and reverse (5'-CCCATCTT GCCTCACTGCACACA-3') primers using the following thermal cycles: initial denaturation at 96°C for 8 min, followed by 32 cycles of denaturation (96°C/1min), annealing (69.5°C/1 min), and extension (72°C/1 min) with a final extension at 72°C for 7 min.

Fisher's exact test was used to assess deviation from Hardy-Weinberg equilibrium. The distribution of categorical variables was examined using the Chi-square test. Logistic regression analysis estimated the genotypic OR of *LCAT* polymorphism for each categorical variable, including combined effects of age

Table 1. Characteristics of the study population

Variables	Subjects with high HDL-C (n = 57)	Subjects with low HDL-C (n = 73)	P value
Sex (M/F) (%)	38/56	61/43	NS
Age (yr)	37 ± 16	41 ± 13	NS
TC (mg/dl)	194 ± 42	168 ± 47	0.001
LDL-C (mg/dl)	104 ± 35	90 ± 28	0.012
TG (mg/dl)	81 ± 42	251 ± 179	0.000
BMI (kg/m ²)	23 ± 3	26 ± 3	0.001
Glucose (mg/dl)	93 ± 9	108 ± 34	0.001
LCAT activity (nmol/ml/h)	103 ± 14	106 ± 15	NS
SBP (mmHg)	113 ± 19	114 ± 17	NS
DBP (mmHg)	73 ± 11	77 ± 9	0.016

BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LCAT, lecithin:cholesterol acyltransferase; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglycerides; DBP, diastolic blood pressure; SBP, systolic blood pressure. NS not significant. Demographics and lipid levels among subjects with high and low HDL-C levels are shown

and sex. Student's *t* test was used to assess differences in LCAT mutant activity in comparison to the wild-type LCAT. SPSS (version 15.0; SPSS, Chicago, IL, USA) was used for data analysis. $P \leq 0.05$ was deemed statistically significant.

RESULTS

The demographic data, clinical status, and biochemical parameters of the studied population are presented in Table 1. As shown in the Table, the mean ± SD age of the extremely high HDL-C group was 37 ± 16 years and that of the extremely low HDL-C group was 41 ± 13 years. BMI, fasting blood sugar, cholesterol, triglyceride, and LDL-C in extremely high HDL-C group were significantly different from the extremely low HDL-C group, whereas LCAT activity did not differ significantly.

Rs5923 is a synonymous variation existing in the exon 6 of LCAT gene. The genotype frequencies of LCAT gene (rs5923) polymorphism in individuals with high and low HDL-C levels are shown in Table 2. The rs5923 polymorphism genotype frequencies were in accordance with Hardy-Weinberg Equilibrium ($K^2 = 0.78$). The genotype (C/C:C/T genotypes) distributions of rs5923 in the high HDL and low HDL-C groups were 94.7%:5.3% and 83.5%: 16.5%, respectively. No individual was homozygote for the TT genotype. The genotype distribution of the SNP was significant between individuals with high and low HDL levels ($P = 0.048$, Table 2). The allele (C:T) distributions of rs5923 in the high and low HDL-C groups were 91.7%: 8.3% and 97.3%: 0.27%, respectively ($P = 0.16$). However, the presence of the T allele did not increase the risk of having a lower HDL level as compared to the C allele (odd ratio [OR] = 3.54, confidence interval [CI]: 0.9-13.21; $P = 0.06$). The

results suggest that rs5923 of LCAT may not contribute to the risk for low HDL susceptibility. The mean values of lipid levels, fasting blood sugar, and LCAT activity among genotypes are shown in Table 3. Among the subjects with low HDL and those with high HDL, no significant differences were observed in the level of clinical factors among the rs5923 genotypes.

DISCUSSION

In the 1980s, low HDL-C levels in serum were identified as a risk factor for coronary artery disease [21]. The low level of HDL-C are a risk factor for metabolic syndrome, which is a disorder with the following medical conditions: abdominal (central) obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, and low HDL levels, which increase the risk for development of CVD [22].

Low levels of HDL-C are common among Iranian population [17]. HDL compared to the other lipoproteins (i.e., very-low-density lipoprotein, intermediate-density lipoprotein, and chylomicrons) is more tightly controlled by genetic factors. For example, in some families with Japanese ancestry, a genetic deficiency of cholesteryl ester transfer protein

Table 2. Genotype frequencies of rs5923 SNP in HDL-C groups

Group	C/C	C/T
Low HDL-C (%)	83.6	16.4
High HDL-C (%)	94.7	5.3

HDL-C, high-density lipoprotein cholesterol; LCAT, lecithin:cholesterol acyltransferase. Genotype frequencies of SNP 4886C/T in the LCAT gene among subjects with low and high HDL-C levels ($P = 0.049$)

Table 3. Mean values of lipids levels, FBS, and LCAT activity among genotypes

rs5923 polymorphism	Total			Low HDL			High HDL		
	CC	CT	P value	CC	CT	P value	CC	CT	P value
HDL-C levels (mg/dl)	50 ± 24	35 ± 18	0.02	28 ± 3	26 ± 2	0.10	74 ± 10	70 ± 4	0.41
TG levels (mg/dl)	171 ± 166	239 ± 182	0.14	106 ± 15	105 ± 21	0.76	81 ± 44	54 ± 12	0.30
LDL levels (mg/dl)	98 ± 32	99 ± 36	0.93	250 ± 192	285 ± 175	0.56	106 ± 35	97 ± 49	0.69
TC levels (mg/dl)	183 ± 48	173 ± 43	0.46	91 ± 27	100 ± 35	0.38	197 ± 43	178 ± 45	0.46
FBS (mg/dl)	99 ± 21	111 ± 48	0.08	170 ± 49	172 ± 45	0.91	92 ± 8	83 ± 4	0.08
BMI (kg/m ²)	25 ± 3	26 ± 3	0.13	105 ± 27	118 ± 52	0.18	23 ± 3	24 ± 3	0.67
LCAT activity (nmol/ml/h)	105 ± 14	103 ± 19	0.80	26 ± 3	27 ± 2	0.48	103 ± 13	98 ± 12	0.57

HDL-C, high-density lipoprotein cholesterol; LCAT, lecithin: cholesterol acyltransferase; LDL-L, low-density lipoprotein; TC, total cholesterol; TG, triglycerides ; FBS, fasting blood glucose. Distribution of mean values with standard deviations of HDL-C levels, LCAT activity among LCAT genotypes

is significantly associated with elevated HDL-C levels [23]. In the current study, we investigated the correlation between a single polymorphism nucleotide of *LCAT* and HDL-C levels. No association was found between the genotypes for the rs5923 polymorphism of the *LCAT* gene and HDL-C levels. Also, no significant correlation was found between LCAT enzyme activity and lipid levels.

LCAT gene is polymorphous in Iranian population, and some of its common variants are the ones previously reported in other Turkish, European, and Canadian societies. In a meta-analysis study performed on 20,562 individuals in Denmark, it has been shown that 1,045 people had rs5923 polymorphism (T-allele frequency: 0.05) [13], which is compatible with our results. In this investigation, the frequency of mutant T allele in the *LCAT* rs5923 polymorphism was 0.058. Also, this finding was consistent with the results of Recalde and co-workers [24] who found that the T-allele frequency of the rs5923 polymorphism was 0.07 in Spanish individuals with hypoalphalipoproteinemia. This frequency is considered as being high in the Turkish population (0.54) [16]. However, according to the reports of NHLBI GO Exome Sequencing Project on 4,348 individuals, the T-allele frequency of the rs5923 polymorphism was 0.098. Furthermore, the T-allele frequency in rs5923 demonstrated a considerable ethnic divergence: 0.212 in the Sub-Saharan African inhabitants, 0.035 in the European population, 0.09 in the African American, while being 0.03 in the Asian population [14].

In the initial analysis of the data, rs5923 showed a significantly higher occurrence in the low HDL than the high HDL levels. However, no significant association was observed among the low HDL levels after analyzing the logistic regression and entering the confounding factors. Since the change in the base of this SNP does not lead to the change in amino acid, non-different presence of rs5923 in both groups is justifiable. Nevertheless, in a study conducted on 100

Turkish citizens, T-allele frequencies of this SNP were obtained 0.54 and 0.37 in the low and high HDL-C groups, respectively ($P = 0.019$) [16]. In another study, the frequencies of the T allele were different between low HDL-C individuals (0.064 and 0.059) and the control groups (0.035 and 0.081) [22]. A plausible reason for this observation is the possible association between the T allele and another allele of the relevant locus (the causative factor on enzyme function) in those populations. Moreover, the proximity of this polymorphism to the coding region of enzyme active site can somehow affect the enzyme activity in that community. Interestingly, in a study conducted by Ashley-Koch *et al.* [25], this SNP showed a significant relationship with the phenotype of pulmonary hypertension in the patients suffering from sickle cell disease. However, this observation has not been confirmed in any other studies.

There are several limitations within the present study. The small number of our samples only covers individuals with no history of statin consumption. The reaction to statins and additional new therapies in order to increase the HDL-C levels could be modulated by LCAT enzyme. Quality rather than quantity of HDL-C provides more information regarding the HDL-C preventive role in cardiovascular effects.

The T-allele frequencies of *LCAT* rs5923 polymorphism were not significantly different in subjects with low and high HDL-C. The fact that there is no association between rs5923 polymorphism and low HDL-C levels probably shows that it is not an important risk factor for HDL-C levels and consequently for CVD.

ACKNOWLEDGMENTS

This investigation was supported by the grant SBUMS/M-1391/278 from Shahid Beheshti University of Medical Sciences, Tehran, Iran. We would like to

express our appreciation to Dr. Yadollah Mehrabi for his assistance in analyzing the data. The participation of the staff of Endocrine Research Center and Tehran Lipid and Glucose Study unit are gratefully acknowledged.

REFERENCES

- Kathiresan S, Manning AK, Demissie S, D'Agostino RB, Surti A, Guiducci C, et al. A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. *BMC Med Genet.* 2007 Sep; 8 Suppl 1:S17.
- Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? *J Lipid Res.* 2010 Aug; 51(8):2058-73.
- Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). *Soz Praventivmed.* 2002; 47(6):408-26.
- Peloso GM, Demissie S, Collins D, Mirel DB, Gabriel SB, Cupples LA, et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. *J Lipid Res.* 2010 Dec; 51(12):3524-32.
- Wang X, Paigen B. Genetics of variation in HDL cholesterol in humans and mice. *Circ Res.* 2005 Jan; 96(1):27-42.
- Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. *Science.* 2004 Aug; 305(5685):869-72.
- Glomset JA. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. *Biochim Biophys Acta.* 1962 Nov; 65:128-35.
- Maeda E, Naka Y, Matozaki T, Sakuma M, Akanuma Y, Yoshino G, et al. Lecithin-cholesterol acyltransferase (LCAT) deficiency with a missense mutation in exon 6 of the LCAT gene. *Biochem Biophys Res Commun.* 1991 Jul; 178(2):460-6.
- Jonas A. Lecithin cholesterol acyltransferase. *Biochim Biophys Acta.* 2000 Dec; 1529(1-3):245-56.
- McLean J, Wion K, Drayna D, Fielding C, Lawn R. Human lecithin-cholesterol acyltransferase gene: complete gene sequence and sites of expression. *Nucleic Acids Res.* 1986 Dec; 14(23):9397-406.
- Calabresi L, Simonelli S, Gomaschi M, Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. *Atherosclerosis.* 2012 Jun; 222(2):299-306.
- Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature.* 2010 Aug; 466(7307):707-13.
- Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. *J Clin Endocrinol Metab.* 2012 Feb; 97(2):E248-56.
- Day IN. DbSNP in the detail and copy number complexities. *Hum Mutat.* 2010 Jan; 31(1):2-4.
- Stenson PD, Ball E, Howells K, Phillips A, Mort M, Cooper DN. Human gene mutation database: towards a comprehensive central mutation database. *J Med Genet.* 2008 Feb; 45(2):124-6.
- Agirbasli D, Cirakoglu B, Eren F, Sumerkan M, Aksoy S, Aral C, et al. Effects of lecithin: cholesterol acyltransferase genotypes, enzyme levels, and activity on high-density lipoprotein levels. *J Clin Lipidol.* 2011 May-Jun; 5(3):152-8.
- Azizi F, Raiszadeh F, Salehi P, Rahmani M, Emami H, Ghanbarian A, et al. Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study. *Nutr Metab Cardiovasc Dis.* 2002 Apr; 12(2):80-9.
- Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. *Trials.* 2009 Jan; 10:5.
- Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, et al. The UCSC Genome Browser database: extensions and updates 2013. *Nucleic Acids Res.* 2013 Jan; 41(Database issue):D64-9.
- Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. *Methods Mol Biol.* 2000; 132:365-86.
- Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med.* 1977 May; 62(5):707-14.
- Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. *J Lipid Res.* 2010 Aug; 51(8):2032-57.
- Yamashita S, Maruyama T, Hirano K, Sakai N, Nakajima N, Matsuzawa Y. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. *Atherosclerosis.* 2000 Oct; 152(2):271-85.
- Recalde D, Cenaarro A, Civeira F, Garcia-Otin AL, Pocovi M. A novel DNA polymorphism (4886C>T) in the human LCAT gene. *Hum Mutat.* 2000 Mar; 15(3):298.
- Ashley-Koch AE, Elliott L, Kail ME, De Castro LM, Jonassaint J, Jackson TL, et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. *Blood.* 2008 Jun; 111(12):5721-6.